Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | RPS6KB2 | Q9UBS0 | 2/20 | 0.37 |
| ▸ | LPL | P06858 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16459658 | 0.80 | HPGD (0.39) | KDM4EMAPTHPGDALOX5PTGS1 | |
| SCHEMBL29616919 | 0.72 | KDM4E (0.61) | KDM4EMAPTHPGDHTTALDH1A1 | |
| SCHEMBL18380643 | 0.72 | KDM4E (0.61) | KDM4EMAPTHPGDHTTALDH1A1 | |
| SCHEMBL471858 | 0.71 | KDM4E (0.60) | KDM4EMAPTHPGDHTTALDH1A1 | |
| SCHEMBL9791116 | 0.71 | KDM4E (0.44) | KDM4EMAPTHPGDHTTALDH1A1 | |
| SCHEMBL14244191 | 0.70 | KDM4E (0.78) | KDM4EMAPTHPGDHTTALDH1A1 | |
| Hydrochloric Acid SCHEMBL11553058 | 0.69 | KDM4E (0.58) | KDM4EMAPTHPGDHTTALDH1A1 | |
| SCHEMBL8855987 | 0.69 | KDM4E (0.58) | KDM4EMAPTHPGDHTTALDH1A1 | |
| SCHEMBL471881 | 0.69 | KDM4E (0.62) | KDM4EMAPTHPGDHTTLMNA | |
| SCHEMBL8855999 | 0.69 | KDM4E (1.00) | KDM4EMAPTHPGDHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318938-B2 | Trans-fused chromenoisoquinolines synthesis and methods for use | PURDUE RESEARCH FOUNDATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318938-B2 | Trans-fused chromenoisoquinolines synthesis and methods for use | PURDUE RESEARCH FOUNDATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-8076330-B2 | Dipeptidyl peptidase-IV inhibitors | AMGEN INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076330-B2 | Dipeptidyl peptidase-IV inhibitors | AMGEN INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553861-B2 | Dipeptidyl peptidase-IV inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553861-B2 | Dipeptidyl peptidase-IV inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-0804420-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | American Cyanamid Company (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5594152-A | Process for the preparation of tricyclic-heterocycles | AMERICAN CYANAMID COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996022292-A1 | TRICYCLIC VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996022282-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5521173-A | TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
| US-5512563-A | TREATING DISEASES CAUSED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1996-04-30 | — | — | US | disclosed |
| CN-1106802-A | Tricyclic benzazepines (aza *) vasopressin antagonists | AMERICAN CYANAMID CO (US) | 1995-08-16 | — | — | CN | disclosed |
| US-5436333-A | Process for the preparation of tricyclic-heterocycles | AMERICAN CYANAMID COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0640592-A1 | N-acylated tricyclic azaheterorings useful as vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1995-03-01 | — | — | EP | disclosed |
| EP-0355710-A2 | Phenylalkylthiophenes and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | DPP4, DPP3, DPP7 | KDM4E 465/4885MAPT 3665/4885HPGD 1513/4885 |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP7 | KDM4E 465/4885MAPT 3665/4885HPGD 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.